Donnelly Brian J 4

What Happened

• Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics (MYGN), received a grant of 226,804 restricted stock units (RSUs) on 2026-03-12. The Form 4 reports the acquisition as 226,804 shares at $0.00 (award/grant). These RSUs are contingent rights to receive common stock upon vesting rather than immediate open-market purchases.

Key Details

• Transaction date: 2026-03-12 (reported on Form 4 filed 2026-03-16).
• Transaction type/code: Award/Grant (A); 226,804 RSUs granted at $0.00 reported value.
• Vesting: Per filing footnote, RSUs are time-based under the 2017 Equity Incentive Plan and vest in three equal annual installments beginning on the first anniversary of the grant date.
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Form 4 filed 2026-03-16 — within the typical 2 business-day reporting window for Form 4 filings.

Context

• These RSUs are compensation/retention awards and do not represent an immediate market purchase or sale. RSUs convert to actual shares only as they vest (per the stated three-year schedule), at which point any resulting shares could be held or sold depending on the insider’s decisions and any applicable company or securities-law restrictions.